Introduction
Homozygous sickle cell (SS) disease is a major cause of morbidity and mortality in Jamaica, with an incidence at birth of 1 in 300 . The clinical course can be very variable, some individuals experiencing painful crises or other complications at an early age, whereas others have few problems. Foetal haemoglobin is one factor thought to contribute to the highly variable clinical course. This is borne out by the relatively benign disease in eastern Saudi Arabia (Perrine et al., 1978) and India (Kar et al., 1986) where HbF levels are generally high, when compared to Africans. Studies within populations of African origin have also shown that high HbF levels are associated with milder disease (Jackson, Odom & Bell, 1961; Serjeant, 1975; Odenheimer et al., 1983 Odenheimer et al., , 1987 . The nature of the relationship between HbF levels and clinical severity remains elusive and it is unclear whether there is a threshold effect (Powars et al., 1984) or whether small increments lead to small improvements in clinical outcome (Platt et al., 1991) .
It was our impression that patients with very low levels of HbF had a more benign disease than would be expected. We tested this hypothesis by comparing the features of a group of patients with steady-state HbF levels below 1% with two control groups with higher HbF levels.
Subjects and methods

Subjects
The study was carried out at the Medical Research Council Laboratories (Jamaica) at the University of the West Indies, Kingston, Jamaica, where analysis of clinic structure revealed 1269 patients with SS disease, born between 1 January 1962 and 30 November 1983. Of these 1269 subjects, average values of steady-state haematology and HbF were available in 927. The study was further limited to paitents followed since 1972 (as more complete haematology was available in this group) and to observation between the ages of 10 and 20 years [as crosssectional stuides show little age-related trend in HbF levels in this age group (Hayes et al., 1985) ]. To be included, each patient must have attended at least twice in that period. Fifty eligible patients had HbF levels below 1% and constituted the study group. The controls comprised 54 patients with average steady-state HbF around the 25th centile (range 2.5±3.4%; control group A) and 60 patients with average steady-state HbF around the 50th centile (range 4.6±5.2%; control group B), these being all the patients whose steady-state HbF fell within that range. The purpose of two control groups was to allow identi®cation of a J-shaped relationship between HbF and severity.
Haematology
Haemoglobin (Hb), mean cell haemoglobin concentration (MCHC), red blood cell count (RBC), mean cell volume (MCV), mean cell haemoglobin (MCH), platelets and nucleated blood cell count (NBC) were measured on an electronic particle counter (Coulter S plus 4, Coulter MaxM, Coulter Electronics, Miami, FL, USA). Packed cell volume (PCV) was measured as a microhaematocrit, and reticulocytes by maunal counting after staining with brilliant cresyl blue. Diagnosis of SS disease was made by standard methods (Serjeant, 1992) . HbF was measured by alkaline denaturation (Betke, Marti & Schlicht, 1959) . The number of a-globin genes was determined in a subset of patients (50% study group, 48% control group A, 30% control group B) from DNA extracted from the buffy coat as previously described (Higgs et al., 1982) . Steady-state haematological indices were expressed as the mean of all values between the ages of 10 and 20 years when the patient was well (without acute crises or chronic conditions likely to in¯uence haematology, but including leg ulcers). Average steady-state Hb, HbA 2 , reticulocytes, PCV, MCHC, RBC, MCV and MCH were approximately normally distributed within the three groups, and the mean values of each group were compared using analysis of variance. For statistical testing of differences in the number of a-globin genes among the groups, homozygotes and heterozygotes were combined because of the small numbers available.
Clinical events
All clinic patients are encouraged to attend for regular appointments when well and at any time when ill. Blood tests are performed on a regular basis, and more frequently if indicated for clinical management. Clinical severity was assessed by the number of events of painful crisis, acute abdominal crisis and the acute chest syndrome between 10 and 20 years. The painful crisis was de®ned as an episode of bone pain suf®cient to interfere with function and require narcotic analgesia; events within 14 days were arbitrarily classed as the same episode. The abdominal painful crisis was de®ned as an episode of localized or generalized pain and tenderness without the characteristics of other medical or surgical problems. The acute chest syndrome was de®ned by radiological evidence of pulmonary in®ltration, usually associated with pleuritic pain, cough, fever and clinical signs of consolidation. For each individual the ®rst occurrence of each event after the age of 10 years was recorded. Incidence rates were calculated from the total number of subjects within a group with an event divided by the years of follow-up prior to the event, expressed as incidence per 100 patient years. Deaths, stroke, splenectomy and leg ulcers from birth to 20 years were also assessed.
Results
Sex, age, mortality and follow-up
No differences occurred among the groups in deaths, emigrations, number of patients below 20 years (not having completed the study period), or years of follow-up (Table 1 ). The average period of follow-up (from age 10 to last visit) was 7.2, 7.6 and 7.9 years for the study group, control group A and control group B, respectively; the minimum period was 10, 14 and 8 months, respectively. Males predominated among the study group and there was a slight excess of females among the control group with higher HbF levels.
Haematology
There were positive linear trends across the three groups for Hb, PCV, MCH and MCV, and a negative trend in HbA 2 ( Table 2) . Comparison of the a-globin gene number among the three groups (Table 3) showed no difference (P 0.57).
Low HbF and sickle cell disease
Clinical history
The number of patients experiencing an incidence of acute painful crisis, abdominal crisis and acute chest syndrome are shown in Table 4 , as are the number of patients experiencing leg ulcers. There were no signi®cant differences among the groups, except for leg ulcers which were signi®cantly less in the study group (P 0.04). There were no differences among the groups in stroke (zero, two and two patients, respectively) or in those having had splenectomy (three, ®ve and seven patients, respectively) (P 0.67).
Discussion
Foetal haemoglobin is believed to in¯uence the clinical severity of homozygous sickle cell disease. In vitro, HbF inhibits polymerization of sickle haemoglobin (Bertles, Rabinowitz & Dobler, 1970) , but the in vivo data are less clear because HbF is only one of many factors in¯uencing clinical severity. In Jamaican studies, HbF appears to signi®cantly in¯uence the incidence of the acute chest syndrome (Bailey et al., 1992) , dactylitis (Stevens et al., 1981; Bailey et al., 1992) , splenomegaly, acute splenic sequestration, death (Stevens et al., 1981) , the perinatal mortality rate in pregnant women homozygous for sickle cell disease (Morris et al., 1994) , growth (Sergeant & Aschcroft, 1973) and disease severity in general (Thomas, Higgs & Serjeant, 1997) . The data on the in¯uence of HbF on painful crises are con¯icting, one Jamaican study showing an effect in males only (Bailey et al., 1992) , another ®nding no protective effect of HbF (Baum et al., 1987 ), yet a clear protective effect was apparent in the Co-operative Study in the USA (Platt et al., 1991) . Powars et al. (1980 Powars et al. ( , 1984 found no linear relationship between HbF and clinical severity, but proposed that there were`threshold levels' above which HbF was an ameliorating factor (10% for stroke, 20% for recurrent events such as painful crises). However, because of differences in the mean ages of subjects, in laboratory methods and in the assessment of clinical severity, these studies are not directly comparable.
The large numbers of patients available to the Jamaican Sickle Cell Clinic has allowed the selection of a group of patients with low HbF levels [similar to those occurring in the normal population (Singer, Chernoff & Singer, 1950) ] who have been compared with two control groups. Selection biases included presentation to the Clinic as well as survival to the age of 10 years. Our study showed positive trends between HbF grouping and Hb, PCV, MCH and MCV, and an inverse relationship with HbA 2 [all relationships previously described (Maude, Hayes & Serjeant, 1987) ]. Regarding the frequency of a-thalassaemia, there were no differences among the groups, although the proportions with abnormalities (homozygous and heterozygous a-thalassaemia combined) accounted for 40% in cases, 35% in control group A and 50% in control group B, greater than the 33% expected in the general SS population (Maude et al., 1985) . These higher levels probably result from a selection bias towards sampling individuals with suspected a-thalassaemia, leaving a likely predominance of normal a-globin gene number among patients not tested.
No differences in acute painful crisis, acute abdominal crisis or acute chest syndrome occurred among the groups, suggesting that the low HbF group was not more seriously affected. Neither does there appear to be a linear relationship between HbF and clinical severity at HbF levels studied. However, males predominated in the study group consistent with the observation that females have higher average levels of HbF. As the pattern of painful crises shows important sex differences, a striking agerelated increase occurring in males between 15 and 30 years, but not in non-pregnant females (Baum et al., 1987) , this excess of males in the study group may mask differences among the groups. Leg ulcers were less common in patients with low HbF levels, affecting 20% compared with almost half of the controls. This ®nding was unexpected and unexplained although it only barely reached signi®cance.
In conclusion, patients with SS disease and low HbF levels do not have more severe disease manifestations than control groups with higher HbF levels. These observations add further evidence to the complexity of the effect of HbF in SS disease and to the lack of a simple relationship between HbF level and clinical severity. Table 4 . Number and incidence rates (to ®rst episode) between 10 and 20 years for painful crises, abdominal crises, acute chest syndrome and number with leg ulcers
